Related Experiment Videos
Identification of the complement iC3b binding site in the beta 2 integrin CR3 (CD11b/CD18)
Summary
Researchers identified the binding site for iC3b on the CR3 receptor, crucial for immune responses. This discovery in the CR3 A-domain has implications for developing new anti-inflammatory drugs.
Area of Science:
- Immunology
- Molecular Biology
- Biochemistry
Background:
- The beta 2 integrin CR3 (CD11b/CD18) plays a key role in inflammation and immune clearance.
- CR3 mediates crucial interactions with complement fragments like iC3b in a divalent cation-dependent manner.
Purpose of the Study:
- To identify the specific iC3b binding site within the CR3 receptor.
- To understand the molecular basis of CR3-iC3b interaction for potential therapeutic targeting.
Main Methods:
- Utilized recombinant protein fragments of the CR3 A-domain.
- Performed direct binding assays with iC3b and identified inhibitory peptides.
- Tested binding inhibition on CR3 expressed by human neutrophils.
Main Results:
- A recombinant CR3 A-domain fragment directly bound iC3b in a cation-dependent manner.
- A specific short linear peptide within the A-domain was identified as the iC3b binding site.
- This peptide inhibited iC3b binding to both the A-domain and native CR3 on neutrophils.
Conclusions:
- The integrin A-domain possesses a major recognition function for iC3b.
- The identified iC3b binding site on CR3 offers a target for novel anti-inflammatory therapeutics.